Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Nextcell Pharma AB is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is distributed to 1 distinct examiner and 1 distinct art unit. KIM, TAEYOON is the busiest examiner, overseeing 1 busiest examiner pending office action.
The 1 distinct art unit is the only group currently reviewing the company's active applications. Since 1 distinct examiner is handling the 1 pending office action, the prosecution outcome is tied to the evaluation of that specific individual. The 1 busiest examiner pending office action represents the totality of the company's current pending workload. Practitioners should focus on the specific standards of the 1 distinct art unit to manage the 1 pending office action effectively.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, TAEYOON | 2 | 51.5% | +52.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19003915 | ALLOGENEIC STEM CELL COMPOSITIONS AND METHODS OF TREATMENT | KIM, TAEYOON | 71d overdue |
| 18041507 | ALLOGENEIC COMPOSITION FOR THE TREATMENT OF COVID-19 | KIM, TAEYOON | 29d |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003915 | ALLOGENEIC STEM CELL COMPOSITIONS AND METHODS OF TREATMENT | KIM, TAEYOON | 1631 | §103§112DP | Non-Final OA | 71d overdue | Pending | Dec 27, 2024 |
| 18041507 | ALLOGENEIC COMPOSITION FOR THE TREATMENT OF COVID-19 | KIM, TAEYOON | 1631 | §103DP | Non-Final OA | 29d | Pending | Feb 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial